Topic: CNSNews.com
Ted Cruz was the benificiary of 65 positive articles about him at CNSNews.com last year -- not a surprise, since Cruz employs the daughter of CNS editor Terry Jeffrey. With a new year comes new opportunities to promote Cruz, and CNS did just that in the first three months of 2023:
- Sen. Ted Cruz: Here's What DOJ Is Really Worried About in the Biden Classified-Documents Case...
- Sen. Ted Cruz Fact-Checks Al Gore’s Claim at World Economic Forum: ‘True’
- ‘CRITICAL’: Sen. Cruz Calls for FBI to ‘Immediately’ Search Hunter Biden’s Home, Offices for Classified Documents
- Sen. Ted Cruz: Special Counsel Must Examine ‘Connections Between Joe Biden and Hunter Biden’
- Sen. Ted Cruz: ‘I’ve Seen the Women Who Were Raped by These Traffickers – and the Democrats Don’t Give a Damn’
- Sen. Ted Cruz: ‘I Want to Start by Doing Something That I Don’t Do Very Often, Which Is Commending Joe Biden'
- Sen. Ted Cruz: 'It Was Out of Touch and It Was Fundamentally Dishonest'
- Sen. Cruz: 3 Facts We’ve Known Since 2020 Prove that COVID-19 Came from a Chinese Government Lab
- Sen. Cruz: Want to Avoid WWIII? 'Don't Elect a Spineless Jellyfish Like Joe Biden to be President'
- Sen. Cruz: Biden’s Happy to Let Your Retirement Take a Hit to Achieve His ESG Goals
- Cruz: ‘The Answer Is Not to Invade Mexico’
- Sen. Cruz: Biden's Budget Full of Leftist Buzzwords: 'Equity,' 'Climate,' Even 'Transgender'
- Sen. Ted Cruz: Trump Indictment Would Be 'Political Persecution' by Manhattan D.A.
- Sen. Cruz: Biden’s Claim Republicans Want to ‘Slash Funding for Border Security’ Is ‘Deranged,’ ‘Pathological Dishonesty’
That's 14 articles to kick off the year. And, no, none of them disclosed the conflict of interest of Cruz employing Jeffrey's daughter.In addition, there was a March 13 column by Brian Garst of the Center for Freedom and Prosperity touting Cruz's purported expertise on drug prices under the gushy headline "Trust Ted Cruz, Not Lina Kahn, on Drug Pricing Reform!":
The Senate recently held a hearing to discuss the Pharmacy Benefit Manager (PBM) Transparency Act, S. 127. The goal of the law is laudable: to make prescription drugs more affordable. Unfortunately, the legislation is just political theater.
There’s little reason to believe greater government involvement in PBMs, which health plans use to negotiate with (and secure savings from) drug manufacturers, is in consumers’ interest. At the hearing, Sen. Cruz pointed out “the FTC has previously conducted robust economic analysis of PBMs and found that PBMs benefit consumers by lowering drug prices.”
[...]
Sen. Cruz said that “it seems the FTC has become a ‘catch-all’ agency that Congress and the White House can use to regulate complex markets like prescription drugs or gas prices even when those markets might be reflecting problems caused by other government policies.”
He’s right; and making matters worse is the fact that the FTC under [Lina] Khan is a disaster. Americans for Tax Reform has already called her out for “[taking] aim at numerous industries including agriculture, health, telecommunications, and technology companies.”
Cruz clearly has a (family) friend in the media at CNS. Too bad CNS is too dishonest to do its proper journalistic duty and disclose that to its readers.
